Based on the Pd-Rx Pharmaceutical stock forecast from 0 analysts, the average analyst target price for Pd-Rx Pharmaceutical is not available over the next 12 months. Pd-Rx Pharmaceutical’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Pd-Rx Pharmaceutical is Bullish , which is based on 5 positive signals and 2 negative signals. At the last closing, Pd-Rx Pharmaceutical’s stock price was USD 5.50. Pd-Rx Pharmaceutical’s stock price has changed by 0% over the past week, +12.02% over the past month and -8.33% over the last year.
No recent analyst target price found for Pd-Rx Pharmaceutical
No recent average analyst rating found for Pd-Rx Pharmaceutical
Company Overview Pd-Rx Pharmaceutical
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company provides approximately 2,600 prepackaged medications; and creams, ointments, ophthalmics, otics, liquids, suspensions, etc. It also offers PD-Rx Net, a web-based application that tracks prescriptions filled at the point of care and print prescription labels for prescription that filled onsite; and manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a convenient handling package. In addition, the company provides professional assistance by staffed pharmacists and physicians; and pharmaceutical sampling program design to reduce MCO's pharmaceutical costs, as well as allows medical professionals to offer pre-filled prescriptions to patients free of charge. It serves physicians, pharmacies, and medical clinics. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is headquartered in Oklahoma City, Oklahoma. Read Less
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company provides approximately 2,600 prepackaged medications; and creams, ointments, ophthalmics, otics, liquids, s...Read More
Frequently Asked Questions About Pd-Rx Pharmaceutical (PDRX) Stock
Stock Target Advisor's fundamental analysis for Pd-Rx Pharmaceutical's stock is Bullish .
Unfortunately we do not have enough data on PDRX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PDRX's stock to indicate what its average analyst target is.
PDRX stock's Price/Earning ratio is 5.09.
Our analysis grades PDRX stock's Price / Earning ratio at A-. This means that PDRX stock's Price/Earning ratio is above 9.999999999999998% of the stocks in the Medical Distribution sector in the OTC exchange.
Based on this PDRX may be undervalued for its sector.
The last closing price of PDRX's stock was USD 5.50.
The most recent market capitalization for PDRX is USD 9.43M.
Unfortunately we do not have enough analyst data on PDRX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pd-Rx Pharmaceutical's stock.
As per our most recent records Pd-Rx Pharmaceutical has 0 Employees.
Pd-Rx Pharmaceutical's registered address is 727 North Ann Arbor, Oklahoma City, OK, United States, 73127.
You can get more information about it from Pd-Rx Pharmaceutical's website at https://www.pdrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PDRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
